Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. It also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, the company offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
Phone858-552-1100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$522.28 million
Profitability
Miscellaneous
Employees1,224
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Quidel (NASDAQ:QDEL) Frequently Asked Questions
What is Quidel's stock symbol?
Quidel trades on the NASDAQ under the ticker symbol "QDEL."
How were Quidel's earnings last quarter?
Quidel Co. (NASDAQ:QDEL) announced its earnings results on Wednesday, May, 8th. The company reported $0.84 earnings per share for the quarter, missing the consensus estimate of $0.98 by $0.14. The firm earned $148 million during the quarter, compared to analysts' expectations of $157.61 million. Quidel had a net margin of 12.98% and a return on equity of 25.33%. Quidel's revenue for the quarter was down 12.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.29 earnings per share. View Quidel's Earnings History.
When is Quidel's next earnings date?
What price target have analysts set for QDEL?
5 brokerages have issued 12 month price objectives for Quidel's stock. Their forecasts range from $63.00 to $80.00. On average, they expect Quidel's stock price to reach $73.60 in the next year. This suggests a possible upside of 34.2% from the stock's current price. View Analyst Price Targets for Quidel.
What is the consensus analysts' recommendation for Quidel?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quidel.
Has Quidel been receiving favorable news coverage?
Media headlines about QDEL stock have been trending negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Quidel earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Quidel's key competitors?
Some companies that are related to Quidel include Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX) and ImmuCell (ICCC).
What other stocks do shareholders of Quidel own?
Who are Quidel's key executives?
Quidel's management team includes the folowing people:
- Mr. Douglas C. Bryant, Pres, CEO & Director (Age 61)
- Mr. Randall J. Steward, Chief Financial Officer (Age 65)
- Mr. Robert J. Bujarski, Sr. VP of Bus. Devel. & Gen. Counsel (Age 51)
- Dr. Werner Kroll, Sr. VP of R&D (Age 62)
- Mr. Edward Keith Russell, Sr. VP of Global Commercial Operations (Age 51)
Who are Quidel's major shareholders?
Quidel's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.75%), ArrowMark Colorado Holdings LLC (2.86%), Macquarie Group Ltd. (2.52%), New York State Common Retirement Fund (1.89%), Dimensional Fund Advisors LP (1.88%) and Eagle Asset Management Inc. (1.61%). Company insiders that own Quidel stock include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Jack W Schuler, Karen Gibson, Kenneth F Buechler, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll. View Institutional Ownership Trends for Quidel.
Which major investors are selling Quidel stock?
QDEL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, ArrowMark Colorado Holdings LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Gabelli Funds LLC, Marshall Wace LLP, Loomis Sayles & Co. L P and Eagle Boston Investment Management Inc.. Company insiders that have sold Quidel company stock in the last year include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Karen Gibson, Kenneth F Buechler, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski and Thomas D Brown. View Insider Buying and Selling for Quidel.
Which major investors are buying Quidel stock?
QDEL stock was acquired by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, Goldman Sachs Group Inc., Kornitzer Capital Management Inc. KS, New Amsterdam Partners LLC NY, Man Group plc, Macquarie Group Ltd., GAM Holding AG and Geode Capital Management LLC. View Insider Buying and Selling for Quidel.
How do I buy shares of Quidel?
Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Quidel's stock price today?
One share of QDEL stock can currently be purchased for approximately $54.85.
How big of a company is Quidel?
Quidel has a market capitalization of $2.18 billion and generates $522.28 million in revenue each year. The company earns $74.18 million in net income (profit) each year or $2.82 on an earnings per share basis. Quidel employs 1,224 workers across the globe.
What is Quidel's official website?
How can I contact Quidel?
Quidel's mailing address is 12544 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at 858-552-1100 or via email at [email protected]
MarketBeat Community Rating for Quidel (NASDAQ QDEL)
MarketBeat's community ratings are surveys of what our community members think about Quidel and other stocks. Vote "Outperform" if you believe QDEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QDEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
